Login to Your Account

Clinic Roundup

Tuesday, January 29, 2013
• Medivir AB, of Stockholm, Sweden, said it entered a nonexclusive collaboration between Janssen Pharmaceuticals Inc., part of Johnson & Johnson, of New Brunswick, N.J., and Idenix Pharmaceuticals Inc., of Cambridge, Mass., for the clinical development of an all-oral (interferon-free) direct-acting antiviral (DAA) hepatitis C (HCV) combination therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription